WORLD JOURNAL OF PLASTIC SURGERY
Tue, Mar 25, 2025
[Archive]
Volume 13, Issue 3 (2024)
WJPS 2024, 13(3): 23-32 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahadoram M, Mohammadianinejad S E, Akade E, Ahadi S, Rasras S. A Focus on Myasthenic Ptosis: The Interface of Medical and Surgical Treatment. WJPS 2024; 13 (3) :23-32
URL: http://wjps.ir/article-1-1324-en.html
URL: http://wjps.ir/article-1-1324-en.html
Mohammad Bahadoram *1 
, Seyed Ehsan Mohammadianinejad1 , Esma'il Akade1 , Shana Ahadi2 , Saleh Rasras2
, Seyed Ehsan Mohammadianinejad1 , Esma'il Akade1 , Shana Ahadi2 , Saleh Rasras2
1- Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Neurosurgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Department of Neurosurgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abstract: (1167 Views)
Ocular ptosis, or drooping of the upper eyelid, has diverse etiologies, including neurologic and non-neurologic causes. Aponeurotic ptosis is a common cause in the elderly and traumatic or mechanical causes can affect any age, mimicking a neurologic cause. The neurologic causes are diverse but especially arise peripherally from pathologies affecting the nerve, neuromuscular junction, and muscles. The choice of treatment depends on the particular cause, but surgical intervention can also be an option in appropriately selected neurological patients whose ptosis remains embarrassing despite the best medical treatment. Myasthenia gravis, an autoimmune disorder targeting the neuromuscular junction, is a significant cause of ocular ptosis. The treatment is mainly by symptomatic and immunosuppressive medications, but surgical interventions, such as blepharoplasty, may be considered in some cases of socially embarrassing ptosis.
References
1. Shahzad B, Siccardi MA. Ptosis. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2024, StatPearls Publishing LLC.; 2024.
2. Jeong JH, Park CS. Evaluating the Correlation between Ptosis Improvement and Immediate Postoperative Lagophthalmos following Blepharoptosis Surgery under General Anesthesia in Pediatric Patients. J Clin Med 2024; 19;13(4):1173. [DOI:10.3390/jcm13041173]
3. Keene KR, Kan HE, van der Meeren S, et al. Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis. J Cachexia Sarcopenia Muscle 2022 Dec;13(6):2820-34. [DOI:10.1002/jcsm.13089]
4. Gooris PJJ, Cornelius C-P. Anatomy of the Orbit: Overall Aspects of the Peri- and Intra Orbital Soft Tissues. In: Gooris PJJ, Mourits MP, Bergsma JE, editors. Surgery in and around the Orbit: CrossRoads. Cham: Springer International Publishing; 2023. p. 59-119. [DOI:10.1007/978-3-031-40697-3_3]
5. Oestreicher J, Mehta S. Complications of blepharoplasty: prevention and management. Plast Surg Int 2012;2012:252368. [DOI:10.1155/2012/252368]
6. Song WC, Kim SJ, Kim SH, Hu KS, Kim HJ, Koh KS. Asymmetry of the palpebral fissure and upper eyelid crease in Koreans. J Plast Reconstr Aesthet Surg 2007;60(3):251-5. [DOI:10.1016/j.bjps.2006.04.027]
7. Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options. Eye (Lond) 2021 Sep;35(9):2468-81. [DOI:10.1038/s41433-021-01547-5]
8. Hamedani AG, Gold DR. Eyelid Dysfunction in Neurodegenerative, Neurogenetic, and Neurometabolic Disease. Front Neurol 2017; 8:329. [DOI:10.3389/fneur.2017.00329]
9. Nichols KK, Malloy KA, Karpecki PM, et al. Topical Review: An Update of Diagnostic and Management Algorithms for Acquired Blepharoptosis. Optom Vis Sci 2022 Mar 1;99(3):230-40. [DOI:10.1097/OPX.0000000000001868]
10. Koka K, Patel BC. Ptosis Correction. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2024, StatPearls Publishing LLC.; 2024.
11. Hirano M, Pitceathly RDS. Progressive external ophthalmoplegia. Handb Clin Neurol 2023;194:9-21. [DOI:10.1016/B978-0-12-821751-1.00018-X]
12. Nalci Baytaroğlu H, Kaya B, Korkusuz P, Hoşal MB. A Study of Histopathologic Evaluation and Clinical Correlation for Isolated Congenital Myogenic Ptosis and Aponeurotic Ptosis. Ophthalmic Plast Reconstr Surg 2020 Jul/Aug;36(4):380-4. [DOI:10.1097/IOP.0000000000001564]
13. Park RB, Akella SS, Aakalu VK. A review of surgical management of progressive myogenic ptosis. Orbit 2023 Feb;42(1):11-24. [DOI:10.1080/01676830.2022.2122514]
14. Pauly M, Sruthi R. Ptosis: Evaluation and management. Kerala Journal of Ophthalmology 2019;31(1):11-6. [DOI:10.4103/kjo.kjo_2_19]
15. Margolin E, Freund P. Third Nerve Palsies: Review. Int Ophthalmol Clin 2019 Summer;59(3):99-112. [DOI:10.1097/IIO.0000000000000279]
16. Wray SH. 83Ptosis and Neuromuscular Syndromes. In: Wray SH, editor. Eye Movement Disorders in Clinical Practice: Oxford University Press; 2014. p. 0. [DOI:10.1093/med/9780199921805.003.0003]
17. Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Ocular myasthenia gravis: a review. Indian J Ophthalmol 2014 Oct;62(10):985-91. [DOI:10.4103/0301-4738.145987]
18. Katyal N, Govindarajan R. Pure Ocular Weakness as the Initial Manifestation of Lambert-Eaton Myasthenic Syndrome. Cureus 2017 Dec 31;9(12):e2007. [DOI:10.7759/cureus.2007]
19. Evangelista T, Hanna M, Lochmüller H. Congenital Myasthenic Syndromes with Predominant Limb Girdle Weakness. J Neuromuscul Dis 2015 Jul 22;2(Suppl 2):S21-s9. [DOI:10.3233/JND-150098]
20. Zoumalan CI, Lisman RD. Evaluation and Management of Unilateral Ptosis and Avoiding Contralateral Ptosis. Aesthetic Surgery Journal 2010;30(3):320-8. [DOI:10.1177/1090820X10374108]
21. Putterman AM. Functional ptosis blepharoplasty diagnostic clamp. Ophthalmic Plast Reconstr Surg 2012 Jul-Aug;28(4):311-2. [DOI:10.1097/IOP.0b013e3182523bc4]
22. Ting SL, Koay AC, Yew YH, Chua CN. Challenges in diagnosis and management of pseudoptosis secondary to asymmetrical skin creases. Med J Malaysia 2011 Jun;66(2):121-3.
23. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med 2021 May 21;10(11). [DOI:10.3390/jcm10112235]
24. Lazaridis K, Tzartos SJ. Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management. Front Neurol 2020;11:596981. [DOI:10.3389/fneur.2020.596981]
25. Marcuse F, Brandts L, Moens D, et al. The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis. European Journal of Neurology 2022 2022/04/01;29(4):1187-97. [DOI:10.1111/ene.15238]
26. Vakrakou AG, Karachaliou E, Chroni E, et al. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Frontiers in Immunology 2023 2023-July-26;14. [DOI:10.3389/fimmu.2023.1212757]
27. Rivner MH, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve 2020 Sep;62(3):333-43. [DOI:10.1002/mus.26985]
28. De Baets M, Stassen MH. The role of antibodies in myasthenia gravis. J Neurol Sci 2002 Oct 15;202(1-2):5-11. [DOI:10.1016/S0022-510X(02)00200-9]
29. Behbehani R. Ocular Myasthenia Gravis: A Current Overview. Eye Brain 2023;15:1-13. [DOI:10.2147/EB.S389629]
30. Singman EL, Matta NS, Silbert DI. Use of the Cogan lid twitch to identify myasthenia gravis. J Neuroophthalmol 2011 Sep;31(3):239-40. [DOI:10.1097/WNO.0b013e3182224b92]
31. Apinyawasisuk S, Zhou X, Tian JJ, Garcia GA, Karanjia R, Sadun AA. Validity of Forced Eyelid Closure Test: A Novel Clinical Screening Test for Ocular Myasthenia Gravis. J Neuroophthalmol 2017 Sep;37(3):253-7. [DOI:10.1097/WNO.0000000000000514]
32. Osher RH, Griggs RC. Orbicularis fatigue: the 'peek' sign of myasthenia gravis. Arch Ophthalmol 1979 Apr;97(4):677-9. [DOI:10.1001/archopht.1979.01020010333009]
33. Engstrom JW. Myasthenia gravis: diagnostic mimics. Semin Neurol 2004 Jun;24(2):141-7. [DOI:10.1055/s-2004-830903]
34. Keene KR, Notting IC, Verschuuren J, et al. Eye Muscle MRI in Myasthenia Gravis and Other Neuromuscular Disorders. J Neuromuscul Dis 2023;10(5):869-83. [DOI:10.3233/JND-230023]
35. Díaz-Manera J, Luna S, Roig C. Ocular ptosis: differential diagnosis and treatment. Curr Opin Neurol 2018 Oct;31(5):618-27. [DOI:10.1097/WCO.0000000000000600]
36. Pascuzzi RM. The edrophonium test. Semin Neurol 2003 Mar;23(1):83-8. [DOI:10.1055/s-2003-40755]
37. Hood L. The Tensilon Test. AJN The American Journal of Nursing 1999;99(5). [DOI:10.1097/00000446-199905000-00026]
38. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig 2011 Oct 1;31(10):691-701. [DOI:10.2165/11593300-000000000-00000]
39. Bindu PS, Nirmala M, Patil SA, Taly AB. Myasthenia gravis and acetylcholine receptor antibodies: a clinico immunological correlative study on South Indian patients. Ann Indian Acad Neurol 2008 Oct;11(4):242-4. [DOI:10.4103/0972-2327.44560]
40. Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis. JAMA Neurol 2015 Oct;72(10):1170-4. [DOI:10.1001/jamaneurol.2015.1444]
41. Chung IY, Sheth SJ, Wells KK, Campbell TG. The Usefulness of Anti-acetylcholine Receptor Binding Antibody Testing in Diagnosing Ocular Myasthenia Gravis. J Neuroophthalmol 2021 Dec 1;41(4):e627-e30. [DOI:10.1097/WNO.0000000000001061]
42. Monte G, Spagni G, Damato V, Iorio R, Marino M, Evoli A. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? J Neurol 2021 May;268(5):1803-7. [DOI:10.1007/s00415-020-10342-3]
43. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 2012 Jul;8(5):427-38. [DOI:10.1586/eci.12.34]
44. Li Y, Peng Y, Yang H. Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med 2023 Apr 15;11(7):290. [DOI:10.21037/atm-19-363]
45. Caress JB, Hunt CH, Batish SD. Anti-MuSK Myasthenia Gravis Presenting With Purely Ocular Findings. Archives of Neurology 2005;62(6):1002-3. [DOI:10.1001/archneur.62.6.1002]
46. Goto T, Kimura A, Masuda A, Mochizuki Y, Gomi F. Clinical features of double seronegative ocular myasthenia gravis. Graefes Arch Clin Exp Ophthalmol 2024 Aug;262(8):2617-23. [DOI:10.1007/s00417-024-06425-w]
47. Vinciguerra C, Bevilacqua L, Lupica A, et al. Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows. Brain Sci 2023 Sep 5;13(9). [DOI:10.3390/brainsci13091286]
48. Gallardo E, Martínez-Hernández E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 2014 Oct;13(10):1003-7. [DOI:10.1016/j.autrev.2014.08.039]
49. Tandan R, Hehir MK, 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 2017 Aug;56(2):185-96. [DOI:10.1002/mus.25597]
50. Patel P, Pobre T. Electrodiagnostic Evaluation of Neuromuscular Junction Disorder. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2024, StatPearls Publishing LLC.; 2024.
51. Rakocevic G, Moster M, Floeter MK. Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment? BMC Neurol 2017 Jun 7;17(1):108. [DOI:10.1186/s12883-017-0891-5]
52. Giannoccaro MP, Paolucci M, Zenesini C, et al. Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis. Neurology 2020 Sep 29;95(13):e1800-e6. [DOI:10.1212/WNL.0000000000010619]
53. Grob SR, Cypen SG, Tao JP. Acquired Ptosis. In: Albert DM, Miller JW, Azar DT, Young LH, editors. Albert and Jakobiec's Principles and Practice of Ophthalmology. Cham: Springer International Publishing; 2022. p. 5647-64. [DOI:10.1007/978-3-030-42634-7_84]
54. Kratky V. Treatment of congenital ptosis. Annals of Eye Science 2020;5:37. [DOI:10.21037/aes-20-102]
55. Brogan K, Farrugia ME, Crofts K. Ptosis Surgery in Patients with Myasthenia Gravis: A Useful Adjunct to Medical Therapy. Semin Ophthalmol 2018;33(3):429-34. [DOI:10.1080/08820538.2017.1284871]
56. Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Trans Am Ophthalmol Soc 2000;98:173-80; discussion 80-1.
57. Litwin AS, Patel B, McNab AA, McCann JD, Leatherbarrow B, Malhotra R. Blepharoptosis surgery in patients with myasthenia gravis. Br J Ophthalmol 2015 Jul;99(7):899-902. [DOI:10.1136/bjophthalmol-2014-306335]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
